Services on Demand
Journal
Article
Indicators
- Cited by SciELO
Related links
- Similars in SciELO
Share
Revista industrial y agrícola de Tucumán
On-line version ISSN 1851-3018
Abstract
VIZGARRA, Oscar N.; PLOPER, L. Daniel; CONTRERAS CUENCA, Pablo D. and GHIO, Ana C.. TUC 241: A new non-traditional bean (Phaseolus vulgaris L.) variety, Cranberry type, for Northwestern Argentina. Rev. ind. agríc. Tucumán [online]. 2006, vol.83, n.1-2, pp.29-37. ISSN 1851-3018.
As a consequence of the low profitability of black and white edible beans, the Estación Experimental Agroindustrial "Obispo Colombres" (EEAOC) started researching on non- traditional dry edible beans, such as Cranberry type, whose trade is characterized by more dependable markets and stable prices. The objective of this work was to present a new cultivar of Cranberry dry edible bean with high tolerance to viruses and capable of replacing the already released commercial varieties in Northwestern Argentina. On the first stage of the project (1987), 50 advanced Cranberry dry edible bean lines were introduced to Tucumán. The materials were obtained from the germplasm collection of the International Center for Tropical Agriculture (CIAT), and were evaluated according to their yield level, commercial quality, growth behavior and tolerance to main diseases. Due to the lack of commercial Cranberry bean cultivars, the red dry edible bean cultivar PVAD 1111 was used as a local control. From 1989 to 1991, the control and the selected lines were evaluated in Yield Comparative Trials in Viclos, La Cocha and Monte Redondo (Tucumán) and Pichanal (Salta). A randomized complete block design was used, with three replications per variety/line in each place/year. Each plot consisted of four six-meter- long lines separated by a distance of 70 cm, with a plant density of 16 plants per meter. The new genotype TUC 241 exhibited the highest yield levels, both general and particular at each location, with a mean production rate of 1570 kg/ha.
Keywords : Genetic improvement; Yield comparative trials; Tolerance to BGMV and BDMV.